Kenneth A Lichtenstein
Overview
Explore the profile of Kenneth A Lichtenstein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
772
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Thompson-Paul A, Palella Jr F, Rayeed N, Ritchey M, Lichtenstein K, Patel D, et al.
AIDS
. 2019 Jul;
33(12):1935-1942.
PMID: 31274539
Objective: Cardiovascular disease (CVD) is a common cause of morbidity and mortality among persons living with HIV (PLWH). We used individual cardiovascular risk factor profiles to estimate heart age for...
2.
Thompson-Paul A, Lichtenstein K, Armon C, Palella Jr F, Skarbinski J, Chmiel J, et al.
Clin Infect Dis
. 2016 Sep;
63(11):1508-1516.
PMID: 27613562
Background: Cardiovascular disease (CVD) risk prediction tools are often applied to populations beyond those in which they were designed when validated tools for specific subpopulations are unavailable. Methods: Using data...
3.
Escota G, Mondy K, Bush T, Conley L, Brooks J, Onen N, et al.
AIDS Res Hum Retroviruses
. 2015 Sep;
32(1):59-67.
PMID: 26366785
HIV-infected persons are living longer on combination antiretroviral therapy (cART) but experiencing more comorbidities including low bone mineral density (BMD). Using data from the Study to Understand the Natural History...
4.
Lichtenstein K, Hart R, Wood K, Bozzette S, Buchacz K, Brooks J
J Acquir Immune Defic Syndr
. 2015 Jul;
69(3):306-11.
PMID: 26181706
Introduction: Statin therapy is effective in the prevention of cardiovascular disease in the general population but has been shown to modestly increase the risk for incident diabetes mellitus (DM). Methods:...
5.
Lichtenstein K, Armon C, Buchacz K, Chmiel J, Buckner K, Tedaldi E, et al.
Prev Chronic Dis
. 2013 Jan;
10:E10.
PMID: 23347705
Introduction: Compliance with National Cholesterol Education Program Adult Treatment Panel III (NCEP) guidelines has been shown to significantly reduce incident cardiovascular events. We investigated physicians' compliance with NCEP guidelines to...
6.
Buchacz K, Baker R, Palella Jr F, Shaw L, Patel P, Lichtenstein K, et al.
Antivir Ther
. 2012 Nov;
18(1):65-75.
PMID: 23111762
Background: Certain sociodemographic subgroups of HIV-infected patients may experience more chronic disease than others due to behavioural risk factors, advanced HIV disease or complications from extended use of combination antiretroviral...
7.
Lichtenstein K, Armon C, Nagabhushanam V, Efaw B, Frazer-Abel A, Hiserote M, et al.
Antivir Ther
. 2012 Sep;
17(7):1301-9.
PMID: 22948290
Background: Despite successful suppression of HIV-1 with HAART, some patients do not have robust immunological recovery. Chronic inflammation from persistent immune activation could contribute to this poor response, resulting in...
8.
Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study
Lichtenstein K, Armon C, Buchacz K, Chmiel J, Buckner K, Tedaldi E, et al.
Clin Infect Dis
. 2010 Jul;
51(4):435-47.
PMID: 20597691
Background: Traditional cardiovascular disease (CVD) risk factors, human immunodeficiency virus (HIV) infection, and antiretroviral (ARV) agents have been associated with CVD events in HIV-infected patients. We investigated the association of...
9.
Buchacz K, Baker R, Palella Jr F, Chmiel J, Lichtenstein K, Novak R, et al.
AIDS
. 2010 May;
24(10):1549-59.
PMID: 20502317
Objectives: To assess the incidence and spectrum of AIDS-defining opportunistic illnesses in the highly active antiretroviral therapy (cART) era. Design: A prospective cohort study of 8070 participants in the HIV...
10.
Lichtenstein K
Curr HIV/AIDS Rep
. 2009 Apr;
6(2):77-82.
PMID: 19358778
Structured treatment interruptions have been studied as a strategy to reduce antiretroviral toxicities and expenditures in the treatment of HIV-infected individuals. Paradoxically, in addition to the increased incidence of death...